Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins
- 1 August 2000
- journal article
- clinical trial
- Published by Elsevier BV in Kidney International
- Vol. 58 (2), 851-858
- https://doi.org/10.1046/j.1523-1755.2000.00234.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsAtherosclerosis, 1996
- Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patientsAtherosclerosis, 1996
- Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal diseaseJournal of Renal Nutrition, 1996
- High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patientsKidney International, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995
- Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acidJournal of Internal Medicine, 1995
- Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementationAtherosclerosis, 1995
- Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patientsThe American Journal of Cardiology, 1995
- Vitamin Levels in Chronic Renal Failure and Need for SupplementationBlood Purification, 1985